Healius Limited (FRA:PGZ)
Germany · Delayed Price · Currency is EUR | Market Cap | 200.68M -37.1% |
| Revenue (ttm) | 831.52M +4.6% |
| Net Income | -251.66M |
| EPS | -0.36 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 595 |
| Open | 0.2600 |
| Previous Close | 0.2460 |
| Day's Range | 0.2600 - 0.2600 |
| 52-Week Range | 0.1700 - 0.6150 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About Healius
Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab Dermatopathology, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healiu... [Read more]
Financial Performance
In fiscal year 2026, Healius's revenue was 1.37 billion, an increase of 2.16% compared to the previous year's 1.34 billion. Losses were -415.60 million, 174.9% more than in 2025.
Financial numbers in AUD Financial StatementsNews
Healius Transcript: AGM 2026
FY 2026 earnings improved, while Q1 FY 2027 pathology revenue and cost trends supported reaffirmed guidance. Shareholders challenged cash generation, returns and remuneration; the board expects positive cash flow in FY 2027 and recorded a first strike on the remuneration report.
Healius Slides: FY 2026
Healius has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 21, 2026.
Healius Earnings Call Transcript: H2 2026
Underlying revenue grew 2.1% to AUD 1.37 billion, with strong cost control driving margin improvement and an 8.1% rise in EBITDA. FY 2027 EBIT is guided at AUD 39.7 million, with continued focus on profitable growth, digital transformation, and cost discipline.
Healius Slides: H2 2026
Healius has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 18, 2026.
Healius Annual report: H2 2026
Healius has published its H2 2026 annual report on August 18, 2026.
Healius Earnings release: H2 2026
Healius released its H2 2026 earnings on August 18, 2026, summarizing the period's financial results.
Healius Annual report: H2 2026
Healius has published its H2 2026 annual report on August 18, 2026.
Healius Earnings release: Trading update
Healius released its earnings on May 12, 2026, summarizing the period's financial results.
Healius Earnings Call Transcript: H1 2026
Revenue grew 3.8% to AUD 688.1 million in H1 FY26, with underlying EBITDA up 13.1% and EBIT improving to AUD 7.9 million. Cost savings, digital transformation, and high-value segment growth are driving margin expansion, with FY26 EBIT expected in line with consensus at around AUD 48 million.
Healius Quarterly report: H1 2026
Healius has published its H1 2026 quarterly earnings report on February 17, 2026.
Healius Slides: H1 2026
Healius has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 17, 2026.
Healius Earnings release: H1 2026
Healius released its H1 2026 earnings on February 17, 2026, summarizing the period's financial results.
Healius Transcript: AGM 2025
The AGM highlighted a successful year with the sale of Lumus Imaging, debt repayment, and a special dividend. Strategic focus remains on digital modernization, operational efficiency, and achieving high single-digit EBIT margins by FY 2027. Shareholders supported all resolutions, and the Board addressed concerns on cash flow, competition, and remuneration alignment.